INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
NASDAQ:IART - US4579852082 - Common Stock
15.99 USD
+0.34 (+2.17%)
15.99 USD
0 (0%)
Overall IART gets a fundamental rating of 3 out of 10. We evaluated IART against 190 industry peers in the Health Care Equipment & Supplies industry. While IART is still in line with the averages on profitability rating, there are concerns on its financial health. IART is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
IART had positive earnings in the past year.
IART had a positive operating cash flow in the past year.
IART had positive earnings in 4 of the past 5 years.
In the past 5 years IART always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of -13.65%, IART is in line with its industry, outperforming 56.32% of the companies in the same industry.
IART has a Return On Equity (-48.20%) which is comparable to the rest of the industry.
IART has a Return On Invested Capital of 4.68%. This is in the better half of the industry: IART outperforms 76.32% of its industry peers.
IART had an Average Return On Invested Capital over the past 3 years of 6.10%. This is below the industry average of 8.46%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.65% | ||
| ROE | -48.2% | ||
| ROIC | 4.68% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
IART has a better Operating Margin (9.46%) than 76.84% of its industry peers.
IART's Operating Margin has declined in the last couple of years.
IART has a Gross Margin of 57.24%. This is comparable to the rest of the industry: IART outperforms 54.74% of its industry peers.
In the last couple of years the Gross Margin of IART has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.46% | ||
| PM (TTM) | N/A | ||
| GM | 57.24% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IART is still creating some value.
Compared to 1 year ago, IART has less shares outstanding
The number of shares outstanding for IART has been reduced compared to 5 years ago.
Compared to 1 year ago, IART has a worse debt to assets ratio.
2.2 Solvency
IART has an Altman-Z score of 1.09. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.09, IART perfoms like the industry average, outperforming 54.21% of the companies in the same industry.
A Debt/Equity ratio of 1.18 is on the high side and indicates that IART has dependencies on debt financing.
The Debt to Equity ratio of IART (1.18) is worse than 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.09 |
ROIC/WACC0.8
WACC5.87%
2.3 Liquidity
IART has a Current Ratio of 1.23. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of IART (1.23) is worse than 80.53% of its industry peers.
A Quick Ratio of 0.73 indicates that IART may have some problems paying its short term obligations.
IART has a Quick ratio of 0.73. This is amonst the worse of the industry: IART underperforms 87.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
IART shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.85%.
The Earnings Per Share has been decreasing by -1.35% on average over the past years.
Looking at the last year, IART shows a small growth in Revenue. The Revenue has grown by 3.53% in the last year.
The Revenue has been growing slightly by 1.20% on average over the past years.
EPS 1Y (TTM)-20.85%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-28.57%
Revenue 1Y (TTM)3.53%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%-0.61%
3.2 Future
The Earnings Per Share is expected to grow by 2.21% on average over the next years.
The Revenue is expected to grow by 3.88% on average over the next years.
EPS Next Y-11.84%
EPS Next 2Y-1.87%
EPS Next 3Y2.21%
EPS Next 5YN/A
Revenue Next Year3.53%
Revenue Next 2Y3.93%
Revenue Next 3Y3.88%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
IART is valuated cheaply with a Price/Earnings ratio of 7.14.
Based on the Price/Earnings ratio, IART is valued cheaply inside the industry as 96.84% of the companies are valued more expensively.
IART's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.06.
A Price/Forward Earnings ratio of 6.49 indicates a rather cheap valuation of IART.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IART indicates a rather cheap valuation: IART is cheaper than 98.95% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of IART to the average of the S&P500 Index (22.69), we can say IART is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.14 | ||
| Fwd PE | 6.49 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IART is valued cheaper than 93.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 9.18 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.87%
EPS Next 3Y2.21%
5. Dividend
5.1 Amount
IART does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
15.99
+0.34 (+2.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners100.14%
Inst Owner Change0.03%
Ins Owners3.31%
Ins Owner Change2.01%
Market Cap1.25B
Analysts54.44
Price Target16.76 (4.82%)
Short Float %10.9%
Short Ratio5.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.27%
Min EPS beat(2)-6.76%
Max EPS beat(2)2.22%
EPS beat(4)3
Avg EPS beat(4)2.45%
Min EPS beat(4)-6.76%
Max EPS beat(4)11.12%
EPS beat(8)3
Avg EPS beat(8)-0.11%
EPS beat(12)6
Avg EPS beat(12)3.26%
EPS beat(16)8
Avg EPS beat(16)3.79%
Revenue beat(2)1
Avg Revenue beat(2)0.78%
Min Revenue beat(2)-1.58%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-0.4%
Min Revenue beat(4)-2.51%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-0.95%
Revenue beat(12)2
Avg Revenue beat(12)-0.82%
Revenue beat(16)3
Avg Revenue beat(16)-0.75%
PT rev (1m)-1.71%
PT rev (3m)-18.44%
EPS NQ rev (1m)-24.66%
EPS NQ rev (3m)-26.62%
EPS NY rev (1m)-1.2%
EPS NY rev (3m)-1.16%
Revenue NQ rev (1m)-1.09%
Revenue NQ rev (3m)-0.74%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.14 | ||
| Fwd PE | 6.49 | ||
| P/S | 0.77 | ||
| P/FCF | N/A | ||
| P/OCF | 17.57 | ||
| P/B | 1.2 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.18 |
EPS(TTM)2.24
EY14.01%
EPS(NY)2.47
Fwd EY15.42%
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)0.91
OCFY5.69%
SpS20.82
BVpS13.33
TBVpS-9.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.65% | ||
| ROE | -48.2% | ||
| ROCE | 5.61% | ||
| ROIC | 4.68% | ||
| ROICexc | 5.16% | ||
| ROICexgc | 18.86% | ||
| OM | 9.46% | ||
| PM (TTM) | N/A | ||
| GM | 57.24% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexcg growth 3Y-1.99%
ROICexcg growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.06 | ||
| Cap/Depr | 79.68% | ||
| Cap/Sales | 7.29% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 23.48% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z | 1.09 |
F-Score5
WACC5.87%
ROIC/WACC0.8
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.85%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-28.57%
EPS Next Y-11.84%
EPS Next 2Y-1.87%
EPS Next 3Y2.21%
EPS Next 5YN/A
Revenue 1Y (TTM)3.53%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%-0.61%
Revenue Next Year3.53%
Revenue Next 2Y3.93%
Revenue Next 3Y3.88%
Revenue Next 5YN/A
EBIT growth 1Y-36.46%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.58%
EBIT Next 3Y10.16%
EBIT Next 5YN/A
FCF growth 1Y-130.53%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-65.94%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%